Essential Biotechnology Presents to Wellcome Trust in London as Finalist for Translation Award

In January 2017, a team from Essential Biotechnology was invited to present to the Wellcome Trust Translation Fund Committee in London, UK. Drs. Clarke and James gave an overview of Essential’s scientific and clinical development programs related to anti-CRR9 cancer therapeutics. The team represented one of a handful of programs worldwide that were invited to present. Thanks to the Trust for their support of anti-CRR9 feasibility studies and the opportunity to visit them.

Essential Biotechnology in the news: News From the Heartland. The Journal of the Heartland Angels

“A protein, CRR9, serves as a nexus for tumor cell survival. It’s located on the cell surface, making it an accessible drug target. By developing antibodies to the CRR9 protein, Essential Biotechnology has devised a method to kill therapy-resistant tumors.” – Jayson Kurfis

See the article here.


Essential Biotechnology is a Semi-Finalist in the 2016 Wisconsin Governor’s Business Plan Contest!

Essential Biotechnology is proud to be among the 53 semifinalists for the 2016 Wisconsin Governor’s Business Plan Contest. Entries will be made available to the Wisconsin Angel Network of accredited investors. Subsequent rounds will determine the dozen contestants to give live presentations at he Wisconsin Entrepreneurs’ Conference in Madison, WI on June 7.